
Croda and Nitech Continuous Technology Collaboration
NiTech Solutions and Croda Europe's joint project on utilizing continuous manufacturing technology has received recognition with two significant industry awards.
NiTech Solutions and Croda Europe's joint project on utilizing continuous manufacturing technology has received recognition with two significant industry awards.
UK specialty chemicals company Croda has signed partnership agreements with US companies Amyris and Botanical Solutions Inc (BSI) to source sustainable vaccine adjuvants.
UK specialty chemicals company Croda International has agreed to buy Solus Biotech, a South Korean company specializing in ceramide and phospholipid technologies and with emerging capabilities in natural retinol. The purchase price is about £232 million on a debt-free, cash-free basis.
UK specialty chemical company Croda International will receive up to $75 million from the US government to expand its US capacity to produce ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.
US food giant Cargill has agreed to buy most of Croda’s Performance Technologies and Industrial Chemicals (PTIC) business for €915 million on a cash-free, debt-free basis. The acquisition of the UK group will boost Cargill’s bio-industrial footprint, better serving manufacturers seeking greener ingredients.
Croda International has announced it is undertaking a strategic review of its Performance Technologies and Industrial Chemicals (PTIC) businesses. The primary aim, said the UK specialty chemicals company, will be to establish what type of ownership structure best serves the businesses going forward and create a stronger platform for its future growth.
Croda Health Care will host a virtual conference on Tuesday 2 – Wednesday 3 February, created for the Pharmaceutical industry.
UK specialty chemical company Croda has agreed to buy Spain’s Iberchem, marking its entry into the flavors and fragrances market. Croda will pay owner French investment group Eurazeo €820 million on a debt-free, cash-free basis.
UK specialty chemical company Croda International has agreed to supply Pfizer with novel excipients used to make the drugmaker’s Covid-19 vaccine candidate. The contract, which is for a term of five years, enables Croda to initially supply four component excipients for the first three years of the agreement.